GLP3-R: Safety Profile & Research Summary
From $69.30 · Lot COAs published for 4 of 4 sizes · Free BAC water + free U.S. shipping · Same-day dispatch before 2 PM ET · FOR RESEARCH USE ONLY
Buy GLP3-R Peptide - all sizes10 PubMed CitationsExpert ReviewedLast Reviewed: July 2026
Research Summary
Foundational Studies
| Study | Type | Subject of Report | Ref |
|---|---|---|---|
| Coskun et al. (2022) | Discovery / proof of concept | Characterization of LY3437943 as a triple glucagon, GIP, and GLP-1 receptor agonist | [1] |
| Urva et al. (2022) | Phase 1b multiple-ascending-dose trial | Clinical pharmacology | [2] |
| Jastreboff et al. (2023) | Phase 2 | Triple-hormone-receptor agonist evaluated in a phase 2 trial | [3] |
| Rosenstock et al. (2023) | Phase 2 | Placebo- and active-controlled parallel-group trial | [4] |
| Sanyal et al. (2024) | Phase 2a (MASLD) | Randomized trial in metabolic dysfunction-associated steatotic liver disease | [5] |
| Urva et al. (2023) | Pharmacodynamics | Reported delay in gastric emptying | [6] |
Mechanistic Themes
- Triple receptor agonism - one peptide engages the GIP, GLP-1, and glucagon receptors
- Graded comparator series - selective, dual, and triple agonists allow receptor contributions to be separated
- Glucose-dependent incretin action - insulinotropic activity in this class is conditioned on ambient glucose
- Investigational status - no regulatory approval in any jurisdiction
For Laboratory Research Only. Not for human use, medical use, diagnostic use, or veterinary use.
ALL ARTICLES AND PRODUCT INFORMATION PROVIDED ON THIS WEBSITE ARE FOR INFORMATIONAL AND EDUCATIONAL PURPOSES ONLY.
In Vitro / Preclinical Disclaimer: The research findings described above were observed in laboratory (in vitro), animal model, and clinical research studies of the pharmaceutical product. Research-grade material supplied by Pure U.S. Peptides is for laboratory research use only. No claims are made regarding human therapeutic applications.
Educational Use Only: This content summarises published laboratory and clinical literature for research reference only. It is not medical advice.
Editorial Research Note
“Research Summary Foundational Studies StudyTypeSubject of ReportRef Coskun et al.”
References
- Coskun T, Urva S, Roell WC, et al. Cell Metab. 2022;34(9):1234-1247.e9.
- Urva S, Coskun T, Loh MT, et al. Lancet. 2022;400(10366):1869-1881.
- Jastreboff AM, Kaplan LM, Frías JP, et al. N Engl J Med. 2023;389(6):514-526.
- Rosenstock J, Frias J, Jastreboff AM, et al. Lancet. 2023;402(10401):529-544.
- Sanyal AJ, Kaplan LM, Frias JP, et al. Nat Med. 2024;30(7):2037-2048.
- Urva S, O'Farrell L, Du Y, et al. The novel GIP, GLP-1 and glucagon receptor agonist retatrutide delays gastric emptying. Diabetes Obes Metab. 2023;25(9):2784-2788.
- Katsi V, Koutsopoulos G, Fragoulis C, Dimitriadis K, Tsioufis K. Biomolecules. 2025;15(6):796.
- Coskun T, Sloop KW, Loghin C, et al. Mol Metab. 2018;18:3-14.
- Hammoud R, Drucker DJ. Beyond the pancreas: contrasting cardiometabolic actions of GIP and GLP1. Nat Rev Endocrinol. 2023;19(4):201-216.
- Samms RJ, Coghlan MP, Sloop KW. Trends Endocrinol Metab. 2020;31(6):410-421.
Related Research Questions
Related research
Browse all research guides in the Peptide Research Library →Want the complete research review?
Buy GLP3-R Peptide - all sizes→FOR RESEARCH USE ONLY
This content is provided for educational and informational purposes only. Products are furnished for in-vitro studies only and are not medicines, drugs, or supplements. Not approved by the FDA to prevent, treat, or cure any condition.